The Role of the IGF Axis in Hepatocarcinogenesis

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

• Publication date

  2003-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1055/s-2004-814151PMID 14710347
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cirrhosis and Hepatocellular Carcinoma: Its Relationship with Hepatitis B Virus Antigen Expression

  2005cited by this paper
• Hepatitis C virus replication is associated with expression of transforming growth factor-α and insulin-like growth factor-II in cirrhotic livers

  2005cited by this paper
• Expression and regulation of the insulin‐like growth factor axis components in rat liver myofibroblasts

  2004cited by this paper
• Activation of insulin-like growth factor II signaling by mutant type p53: physiological implications for potentiation of IGF-II signaling by p53 mutant 249.

  2003cited by this paper
• Glucosamine induces resistance to insulin-like growth factor I (IGF-I) and insulin in Hep G2 cell cultures: biological significance of IGF-I/insulin hybrid receptors.

  2003cited by this paper
• PTEN modulates insulin‐like growth factor II (IGF‐II)‐mediated signaling; the protein phosphatase activity of PTEN downregulates IGF‐II expression in hepatoma cells

  2003cited by this paper
• A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma.

  2003cited by this paper
• Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis

  2003cited by this paper
• Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis.

  2003cited by this paper
• DIABETIC RATS

  2003cited by this paper
• The insulin-like growth factor system and cancer.

  2003cited by this paper
• Decreased intracellular degradation of insulin‐like growth factor binding protein‐3 in cathepsin L‐deficient fibroblasts

  2002cited by this paper
• Altered expression of low affinity insulin-like growth factor binding protein related proteins in hepatoblastoma.

  2002cited by this paper
• IGFs and IGFBPs: role in health and disease.

  2002cited by this paper
• M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan

  2002cited by this paper
• A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation.

  2002cited by this paper
• Increases in Free, Unbound Insulin-like Growth Factor I Enhance Insulin Responsiveness in Human Hepatoma G2 Cells in Culture*

  2002cited by this paper
• IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms.

  2002cited by this paper
• Serum insulin‐like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis

  2002cited by this paper
• Cellular actions of the insulin-like growth factor binding proteins.

  2002cited by this paper
• Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma.

  2002cited by this paper
• Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.

  2001cited by this paper
• Abnormal nucleotide repeat sequence in the TGF‐βRII gene in hepatocellular carcinoma and in uninvolved liver tissue

  2001cited by this paper
• Hepatitis C virus core protein transactivates insulin-like growth factor II gene transcription through acting concurrently on Egr1 and Sp1 sites.

  2001cited by this paper
• Methylation changes in the human IGF2 p3 promoter parallel IGF2 expression in the primary tumor, established cell line, and xenograft of a human hepatoblastoma.

  2001cited by this paper
• Factors regulating insulin-like growth factor binding protein-3 secretion from human hepatoma (HepG2) cells.

  2001cited by this paper
• Expression of insulin like growth factor II and its receptor in hepatocellular carcinogenesis.

  2001cited by this paper
• Association between insulin‐like growth factor‐2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

  2001cited by this paper
• Activation of the IGF-II gene by HBV-X protein requires PKC and p44/p42 map kinase signalings.

  2001cited by this paper
• Regulation of the components of the 150 kDa IGF binding protein complex in cocultures of rat hepatocytes and Kupffer Cells by 3′,5′‐cyclic adenosine monophosphate

  2001cited by this paper
• Altered expression of members of the IGF-axis in hepatoblastomas

  2000cited by this paper
• Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver.

  2000cited by this paper
• Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma

  2000cited by this paper
• Lack of frameshift mutations at coding mononucleotide repeats in hepatocellular carcinoma in Japanese patients

  2000cited by this paper
• Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities.

  2000cited by this paper
• Insulin-like growth factor I receptor signaling--overlapping or redundant pathways?

  2000cited by this paper
• Genetics of hepatocellular carcinoma.

  2000cited by this paper
• Analysis of the IGF Axis in Preneoplastic Hepatic Foci and Hepatocellular Neoplasms Developing after Low-Number Pancreatic Islet Transplantation into the Livers of Streptozotocin Diabetic Rats

  2000cited by this paper
• The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma

  2000cited by this paper
• The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.

  2000cited by this paper
• Methylation and downregulated expression of mac25/insulin-like growth factor binding protein-7 is associated with liver tumorigenesis in SV40T/t antigen transgenic mice, screened by restriction landmark genomic scanning for methylation (RLGS-M).

  2000cited by this paper
• Insulin‐like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men

  2000cited by this paper
• Insulin-like growth factor binding protein (IGFBP) proteolysis: occurrence, identification, role and regulation.

  1999cited by this paper
• Type-2 IGF Receptor: A Multi-Ligand Binding Protein

  1999cited by this paper
• Failure to detect genetic alteration of the mannose‐6‐phosphate/insulin‐like growth factor 2 receptor (M6P/IGF2R) gene in hepatocellular carcinomas in japan

  1999cited by this paper
• Insulin and insulin‐like growth factor‐1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: Differential effects on signal transduction pathways

  1999cited by this paper
• A Family of Insulin-Like Growth Factor II mRNA-Binding Proteins Represses Translation in Late Development

  1999cited by this paper
• Insulin-like Growth Factor II Signaling in Neoplastic Proliferation Is Blocked by Transgenic Expression of the Metalloproteinase Inhibitor Timp-1

  1999cited by this paper
• Normal growth and development in the absence of hepatic insulin-like growth factor I.

  1999cited by this paper
• A Novel Cytoplasmic Protein with RNA-binding Motifs Is an Autoantigen in Human Hepatocellular Carcinoma

  1999cited by this paper
• The insulin-like growth factor-binding protein (IGFBP) superfamily.

  1999cited by this paper
• Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice.

  1999cited by this paper
• Down‐regulation of insulin‐like growth factor binding proteins and growth modulation in hepatoma cells by retinoic acid

  1999cited by this paper
• Insulin-like growth factor signaling pathways in rat hepatic stellate cells: importance for deoxyribonucleic acid synthesis and hepatocyte growth factor production.

  1999cited by this paper
• Disruption of Ligand Binding to the Insulin-like Growth Factor II/Mannose 6-Phosphate Receptor by Cancer-associated Missense Mutations*

  1999cited by this paper
• Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers.

  1999cited by this paper
• The IGF-I receptor in cancer research.

  1999cited by this paper
• Characterization of the IGF axis components in isolated rat hepatic stellate cells

  1998cited by this paper
• The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4

  1998cited by this paper
• Insulin-like growth factor-I effect on chicken hepatoma cells (LMH) is inhibited by endogenous IGF-binding proteins.

  1998cited by this paper
• Reactivation of the maternally imprinted IGF2 allele in TGFα induced hepatocellular carcinomas in mice

  1998cited by this paper
• Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC).

  1998cited by this paper
• Expression and regulation of the insulin-like growth factor-1 receptor by growing and quiescent H4IIE hepatoma.

  1998cited by this paper
• Allelic imbalance of insulin‐like growth factor II gene expression in cancerous and precancerous lesions of the liver

  1998cited by this paper
• Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma.

  1998cited by this paper
• Biophysical and Biological Properties of Naturally Occurring High Molecular Weight Insulin-like Growth Factor II Variants*

  1997cited by this paper
• Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II.

  1997cited by this paper
• Insulin-like growth factor binding proteins and their role in controlling IGF actions.

  1997cited by this paper
• Hepatocellular neoplasms induced by low-number pancreatic islet transplants in streptozotocin diabetic rats.

  1997cited by this paper
• Mutagenic and epigenetic effects of DNA methylation.

  1997cited by this paper
• Imprinted genes in liver carcinogenesis

  1997cited by this paper
• Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma.

  1997cited by this paper
• Altered transcriptional regulation of the insulin‐like growth factor 2 gene in human hepatocellular carcinoma

  1997cited by this paper
• Epidemiological characteristics and risk factors of hepatocellular carcinoma

  1997cited by this paper
• Transforming growth factor-beta and cancer: a love-hate relationship?

  1997cited by this paper
• Deletion of the M6P/IGF2r gene in primary hepatocellular carcinoma.

  1997cited by this paper
• Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

  1997cited by this paper
• Role of the IGF-I receptor in mutagenesis and tumor promotion.

  1997cited by this paper
• Characterization of Insulin-Like Growth Factor (IGF)-I-Receptor Binding Sites during In Vitro Transformation of Rat Hepatic Stellate Cells to Myofibroblasts

  1996cited by this paper
• Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinoma and underlying disease.

  1996cited by this paper
• Altered liver acini induced in diabetic rats by portal vein islet isografts resemble preneoplastic hepatic foci in their enzymic pattern.

  1996cited by this paper
• Synthesis of insulinlike growth factor binding proteins and of the acid‐labile subunit in primary cultures of rat hepatocytes, of Kupffer cells, and in cocultures: Regulation by insulin, insulinlike growth factor, and growth hormone

  1996cited by this paper
• Soluble insulin-like growth factor-II/mannose 6-P receptor inhibits deoxyribonucleic acid synthesis in cultured rat hepatocytes.

  1996cited by this paper
• Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma

  1996cited by this paper
• Cathepsin D, B and L circulating levels as prognostic markers of malignant progression.

  1996cited by this paper
• Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product.

  1996cited by this paper
• Promoter-specific Modulation of Insulin-like Growth Factor II Genomic Imprinting by Inhibitors of DNA Methylation*

  1996cited by this paper
• Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level.

  1996cited by this paper
• Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus–related chronic hepatitis, cirrhosis, and hepatocellular carcinoma

  1996cited by this paper
• Pathogenesis of hepatocellular carcinoma: sequential cellular, molecular, and metabolic changes.

  1996cited by this paper
• Effect of insulin-like growth factor II on uptake of arylsulfatase A by cultured rat hepatocytes and Kupffer cells.

  1995cited by this paper
• Insulin-like growth factors and their binding proteins: biological actions.

  1995cited by this paper
• Differential expression of transforming growth factor a and insulin-like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma

  1995cited by this paper
• Differential expression of transforming growth factor alpha and insulin-like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma.

  1995cited by this paper
• Cellular localization and hormonal regulation of biosynthesis of insulin-like growth factor binding proteins and of the acid-labile subunit within rat liver.

  1995cited by this paper
• M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity

  1995cited by this paper
• Posttranscriptional regulation of insulin-like growth factor II mRNA.

  1995cited by this paper
• Transforming Growth Factor‐Beta Receptors and Mannose 6‐Phosphate/Insulin‐Like Growth Factor‐II Receptor Expression in Human Hepatocellular Carcinoma

  1995cited by this paper
• Loss of heterozygosity of imprinted genes in SV40 t/T antigen-induced hepatocellular carcinomas.

  1995cited by this paper
• Synthesis of insulin-like growth factor binding proteins and of the acid-labile subunit of the insulin-like growth factor ternary binding protein complex in primary cultures of human hepatocytes.

  1995cited by this paper

• IGF1R promotes radiation-induced HSCs activation by regulating DNA-PKcs-mediated DNA damage repair

  2025cites this paper
• Identification of a small-molecule targeting PLAGL2 DNA-binding domain inhibits extracellular matrix formation and enhances lenvatinib sensitivity in hepatocellular carcinoma

  2025cites this paper
• Exploring the Epidemiologic Burden, Pathogenetic Features, and Clinical Outcomes of Primary Liver Cancer in Patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Scoping Review

  2025influential citation
• Liver-specific actions of GH and IGF1 that protect against MASLD

  2024cites this paper
• Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis

  2024cites this paper
• HCC is associated with diabetes and longitudinal blood glucose control in a national cohort with cirrhosis

  2023cites this paper
• Role of lncRNAs in hepatocellular carcinoma.

  2023cites this paper
• Reduced Klotho expression and its prognostic significance in canine hepatocellular carcinoma.

  2022cites this paper
• Aflatoxins exposition in the agrifood industry workers

  2020cites this paper
• The association of nonalcoholic steatohepatitis and hepatocellular carcinoma

  2020cites this paper
• Aflatoxins exposition in the agri-food industry workers

  2020cites this paper
• Diosmin anti-tumor efficacy against hepatocellular carcinoma

  2019cites this paper
• Activation of Viruses by Host Proteases

  2019cites this paper
• Analysis of miRNA expression profiles in the liver of ClockΔ19 mutant mice

  2019cites this paper
• Alteration of oncogenic IGF-II gene methylation status associates with hepatocyte malignant transformation.

  2019cites this paper
• Long non‐coding RNA deleted in lymphocytic leukaemia 1 promotes hepatocellular carcinoma progression by sponging miR‐133a to regulate IGF‐1R expression

  2019cites this paper
• Novel Therapeutic Targets for Hepatocellular Carcinoma Treatment

  2019cites this paper
• 40 YEARS of IGF1: Understanding the tissue-specific roles of IGF1/IGF1R in regulating metabolism using the Cre/loxP system.

  2018cites this paper
• Somatostatin in hepatocellular carcinoma: experimental and therapeutic implications

  2018cites this paper
• Interested in publishing with us ? Contact book

  2018cites this paper
• MicroRNA-302a inhibits osteosarcoma cell migration and invasion by directly targeting IGF-1R

  2018cites this paper
• Effect of Splenectomy on Serum Cytokine Profiles in Hepatitis B Virus-Related Cirrhosis Patients with Portal Hypertension

  2018cites this paper
• Host Cell Proteases: Cathepsins

  2018cites this paper
• 2 Novel Therapeutic Targets for Hepatocellular Carcinoma Treatment

  2017cites this paper
• Differential Expression of Glypican-3 and Insulin–Like Growth Factor-II mRNAs and Alpha-Fetoprotein and Ki-67 Markers in HCV Related Hepatocellular Carcinomas In Egyptian Patients

  2017cites this paper
• Role of anti-aging gene klotho in oral and gastro-intestinal cancers

  2017cites this paper
• Expression levels of microRNA‑455 and its potential functions by targeting IGF‑1R in melanoma.

  2017cites this paper
• IGFBP7 Deletion Promotes Hepatocellular Carcinoma.

  2017cites this paper
• Network module‐based model in the differential expression analysis for RNA‐seq

  2017cites this paper
• IGF-IEc expression is increased in secondary compared to primary foci in neuroendocrine neoplasms

  2017cites this paper
• Interdependent and independent multidimensional role of tumor microenvironment on hepatocellular carcinoma

  2017cites this paper
• MicroRNA-497 inhibits tumor growth through targeting insulin receptor substrate 1 in colorectal cancer

  2017cites this paper
• MiR-30e inhibits tumor growth and chemoresistance via targeting IRS1 in Breast Cancer

  2017cites this paper
• MicroRNA-184 inhibits cell proliferation and metastasis in human colorectal cancer by directly targeting IGF-1R.

  2017cites this paper
• Associations of Calcium and Milk Product Intakes with Incident, Sporadic Colorectal Adenomas

  2017cites this paper
• MicroRNA-592 targets IGF-1R to suppress cellular proliferation, migration and invasion in hepatocellular carcinoma

  2017cites this paper
• Chapter 13 Insulin-Like Growth Factor-II : Molecular-Targeted Therapy for Hepatocellular Carcinoma

  2017cites this paper
• Bariatric Surgery for the Treatment of Nonalcoholic Fatty Liver Disease: Is Vertical Sleeve Gastrectomy the Best Future Option?

  2016cites this paper
• The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models

  2016cites this paper
• Downregulation of IGF-1 receptor occurs after hepatic linage commitment during hepatocyte differentiation from human embryonic stem cells.

  2016cites this paper
• The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment.

  2015cites this paper
• Daintain/AIF-1 accelerates the activation of insulin-like growth factor-1 receptor signaling pathway in HepG2 cells.

  2015cites this paper
• Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.

  2015cites this paper
• MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma

  2015cites this paper
• Chemopreventive Potential of Green Tea Catechins in Hepatocellular Carcinoma

  2015cites this paper
• Prognostic Significance of p53, mTOR, c-Met, IGF-1R, and HSP70 Overexpression after the Resection of Hepatocellular Carcinoma

  2014influential citation
• Prediagnostic plasma testosterone, sex hormone‐binding globulin, IGF‐I and hepatocellular carcinoma: Etiological factors or risk markers?

  2014cites this paper
• Insulin-like growth factor-1 prevents miR-122 production in neighbouring cells to curtail its intercellular transfer to ensure proliferation of human hepatoma cells

  2014influential citation
• Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study

  2014cites this paper
• MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling.

  2014cites this paper
• The insulin-like growth factor-I receptor inhibitor picropodophyllin-induced selective apoptosis of hepatocellular carcinoma cell through a caspase-dependent mitochondrial pathway.

  2014cites this paper
• Biomarkers and Personalized Sorafenib Therapy

  2014cites this paper
• Signals Triggering Proliferation of Hepatocellular Carcinoma

  2014cites this paper
• Benzylidene‐indolinones are effective as multi‐targeted kinase inhibitor therapeutics against hepatocellular carcinoma

  2014cites this paper
• Glycogen Synthase Kinase-3β Is Associated with the Prognosis of Hepatocellular Carcinoma and May Mediate the Influence of Type 2 Diabetes Mellitus on Hepatocellular Carcinoma

  2014cites this paper
• Biomarkers for Diagnosis and Metastasis of Hepatocellular Carcinoma

  2014cites this paper
• Biomarkers in Esophageal Adenocarcinoma

  2014cites this paper
• Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring

  2013cites this paper
• βKlotho Suppresses Tumor Growth in Hepatocellular Carcinoma by Regulating Akt/GSK-3β/Cyclin D1 Signaling Pathway

  2013cites this paper
• The evolving landscape of therapeutic drug development for hepatocellular carcinoma.

  2013cites this paper
• Insulin-Like Growth Factor-II: Molecular-Targeted Therapy for Hepatocellular Carcinoma

  2013cites this paper
• Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents.

  2013cites this paper
• IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic action is independent of IGF2/PI3K signaling.

  2013cites this paper
• Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma.

  2013cites this paper
• [Current status of molecular targeted therapies in hepatocellular carcinoma].

  2013cites this paper
• The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives.

  2013cites this paper
• Molecular targeted therapy for hepatocellular carcinoma: current and future.

  2013cites this paper
• Insulin Resistance and Other Metabolic Risk Factors

  2013cites this paper
• The Value of Measurement of Circulating Tumour Cells in Hepatocellular Carcinoma

  2013cites this paper
• Posttranscriptional Regulation of Insulin Family Ligands and Receptors

  2013cites this paper
• Molecular Targeted Therapy of Hepatocellular Carcinoma

  2013cites this paper
• Epigenetic Alterations of Hepatic IGF-II Gene Promoter and IGF-II Abnormal Expression in HBV-Related Hepatocellular Carcinoma

  2013cites this paper
• Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.

  2012cites this paper
• Insulin-like growth factor 2 gene methylation in peripheral blood mononuclear cells of patients with hepatitis C related cirrhosis or hepatocellular carcinoma.

  2012cites this paper
• Preclinical Development Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH 717454 Is Reversed by IGF2

  2012cites this paper
• Novel Therapeutic Targets for Hepatocellular Carcinoma Treatment

  2012cites this paper
• Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

  2012cites this paper
• Aflatoxin B1 Up-Regulates Insulin Receptor Substrate 2 and Stimulates Hepatoma Cell Migration

  2012influential citation
• Aneuploidy and Epithelial Cancers: The Impact of Aneuploidy on the Genesis, Progression and Prognosis of Colorectal and Breast Carcinomas

  2012cites this paper
• Target Therapy for Hepatocellular Carcinoma

  2012cites this paper
• Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma.

  2012cites this paper
• Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma

  2011cites this paper
• Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma.

  2011cites this paper
• Insulin-like Growth Factor System in Hepatocarcinogenesis

  2011cites this paper
• Initial testing (stage 1) of the IGF‐1 receptor inhibitor BMS‐754807 by the pediatric preclinical testing program

  2011cites this paper
• Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma.

  2011cites this paper
• Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma.

  2011cites this paper
• IGF-I and IGFBP-3 before and after inpatient alcohol detoxification in alcohol-dependent subjects

  2011cites this paper
• Insulin‐like growth factor‐I and the liver

  2011cites this paper
• Insulin-like Growth Factor System in Hepatocarcinogenesis

  2011cites this paper
• Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases.

  2011cites this paper
• Novel molecular therapies in hepatocellular carcinoma

  2011cites this paper
• Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2

  2011cites this paper
• Bedeutung eines neuen IGF-1-Rezeptor- Tyrosinkinase-Inhibitors für Zellproliferation, Signaltransduktion und Regulation der Sekretion in neuroendokrinen Tumorzellen

  2011cites this paper
• The IGF2 mRNA binding protein p62 as a regulator of IGF2 and H19 expression - potential implications in tumorigenesis

  2011cites this paper
• Biological Effects of Calorie Restriction: Implications for Modification of Human Aging

  2010cites this paper
• Characteristics of hepatic igf-ii expression and monitored levels of circulating igf-ii mRNA in metastasis of hepatocellular carcinoma.

  2010cites this paper
• Caloric restriction: from soup to nuts.

  2010cites this paper
• Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma.

  2010cites this paper
• Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma.

  2010cites this paper